Progyny Inc
NASDAQ:PGNY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Progyny Inc
NASDAQ:PGNY
|
US |
|
Fluor Corp
NYSE:FLR
|
US |
|
D
|
Diageo PLC
XETRA:GUI
|
UK |
Progyny Inc
Progyny sells fertility and family-building benefits to employers. It helps companies give workers access to fertility testing, IVF, egg freezing, donor services, and related care through a network of specialized doctors and clinics. Instead of being a clinic itself, Progyny acts as the benefits manager that organizes the care pathway and helps patients navigate a complex treatment process. Its main customers are employers that want to offer fertility coverage as part of their health benefits, along with the employees and dependents who use those benefits. Progyny makes money by charging employers for access to its benefit plans and care management services, and in some cases by earning fees tied to the use of its pharmacy and care coordination programs. The company sits between employers, patients, and fertility providers, helping to direct patients to the right care while making the benefit easier to manage. What makes Progyny different is its focus on a very specific type of health benefit that is expensive, emotionally difficult, and often confusing to use. It is not a broad health insurer or a general employee benefits company. Its role is to package fertility care into a structured benefit, coordinate services across providers, and give employers a clear way to offer this kind of coverage.
Progyny sells fertility and family-building benefits to employers. It helps companies give workers access to fertility testing, IVF, egg freezing, donor services, and related care through a network of specialized doctors and clinics. Instead of being a clinic itself, Progyny acts as the benefits manager that organizes the care pathway and helps patients navigate a complex treatment process.
Its main customers are employers that want to offer fertility coverage as part of their health benefits, along with the employees and dependents who use those benefits. Progyny makes money by charging employers for access to its benefit plans and care management services, and in some cases by earning fees tied to the use of its pharmacy and care coordination programs. The company sits between employers, patients, and fertility providers, helping to direct patients to the right care while making the benefit easier to manage.
What makes Progyny different is its focus on a very specific type of health benefit that is expensive, emotionally difficult, and often confusing to use. It is not a broad health insurer or a general employee benefits company. Its role is to package fertility care into a structured benefit, coordinate services across providers, and give employers a clear way to offer this kind of coverage.
Quarter: Progyny said first quarter revenue was at the high end of expectations, while net income, EPS and adjusted EBITDA all came in above guidance.
Outlook: Management raised full-year expectations for adjusted EBITDA, net income and EPS, and said second-quarter and full-year ranges imply sequential growth from Q1.
Demand: The company described early selling-season activity as stronger than last year, with especially good traction from health plan partners, direct demand generation and RFPs from competitors' clients.
Renewals: Renewal risk has been reduced, with some of the largest clients already giving favorable notices and the remaining renewal exposure at its lowest level at this point in prior years.
Capital returns: Progyny completed its $200 million share repurchase program, buying back more than 5.5 million shares in the quarter and about 8.8 million shares in total under the program.
